Tocilizumab in the treatment of rheumatoid arthritis and beyond

References

• Helmick CG Felson DT Lawrence RC National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I Arthritis Rheum 2008 58 1 15 25 18163481
   PubMed Web of Science ®Google Scholar
• Majithia V Geraci SA Rheumatoid arthritis: diagnosis and management Am J Med 2007 120 11 936 939 17976416
   PubMed Web of Science ®Google Scholar
• Smolen JS Aletaha D Koeller M Weisman MH Emery P New therapies for treatment of rheumatoid arthritis Lancet 2007 370 9602 1861 1874 17570481
   PubMed Web of Science ®Google Scholar
• Jackson CG Williams HJ Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection Drugs 1998 56 3 337 344 9777310
   PubMed Web of Science ®Google Scholar
• Elliott MJ Maini RN Feldmann M Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 1994 344 8930 1105 1110 7934491
   PubMed Web of Science ®Google Scholar
• Nam JL Winthrop KL van Vollenhoven RF Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA Ann Rheum Dis 2010 69 6 976 986 20447957
   PubMed Web of Science ®Google Scholar
• Boers M Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann Intern Med 2009 151 9 668 669 19884628
   PubMed Web of Science ®Google Scholar
• Nishimoto N Kishimoto T Humanized antihuman IL-6 receptor antibody, tocilizumab Handb Exp Pharmacol 2008 181 151 160 18071945
   PubMedGoogle Scholar
• Kishimoto T Interleukin-6: from basic science to medicine – 40 years in immunology Annu Rev Immunol 2005 23 1 21 15771564
   PubMed Web of Science ®Google Scholar
• Hirano T Matsuda T Turner M Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis Eur J Immunol 1988 18 11 1797 1801 2462501
   PubMed Web of Science ®Google Scholar
• Shahrara S Huang Q Mandelin AM2nd Pope RM TH-17 cells in rheumatoid arthritis Arthritis Res Ther 2008 10 4 R93 18710567
   PubMed Web of Science ®Google Scholar
• Sack U Kinne RW Marx T Heppt P Bender S Emmrich F Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis Rheumatol Int 1993 13 2 45 51 8356390
   PubMed Web of Science ®Google Scholar
• Kotake S Sato K Kim KJ Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation J Bone Miner Res 1996 11 1 88 95 8770701
   PubMed Web of Science ®Google Scholar
• Mihara M Kasutani K Okazaki M Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Int Immunopharmacol 2005 5 12 1731 1740 16102523
   PubMed Web of Science ®Google Scholar
• Choy EH Isenberg DA Garrood T Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial Arthritis Rheum 2002 46 12 3143 3150 12483717
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Committee to Reevaluate Improvement Criteria A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response Arthritis Rheum 2007 57 2 193 202 17330293
   PubMed Web of Science ®Google Scholar
• Navarro-Millán I Singh JA Curtis JR Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor Clin Ther 2012 34 4 788 802. e3 22444783
   PubMed Web of Science ®Google Scholar
• Roche 2009 RoACTEMRA [summary of product characteristics] prescribing information Welwyn Garden City Roche Registration Limited 1 2009
   Google Scholar
• Levi M Grange S Frey N Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis J Clin Pharmacol 2013 53 2 151 159 23436260
   PubMed Web of Science ®Google Scholar
• Actemra® (tocilizumab) [prescribing information] South San Francisco Genentech, Inc. 2010
   Google Scholar
• European Medicines Agency Assessment Report for RoActemra London European Medicines Agency 2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000955/WC500111086.pdf Accessed January 23, 2014
   Google Scholar
• Smolen JS Landewé R Breedveld FC EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann Rheum Dis Epub 10 25 2013
   Google Scholar
• Felson DT Anderson JJ Boers M American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 1995 38 6 727 735 7779114
   PubMed Web of Science ®Google Scholar
• van der Heijde DM van’t Hof MA van Riel PL Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score Ann Rheum Dis 1990 49 11 916 920 2256738
   PubMed Web of Science ®Google Scholar
• Nishimoto N Miyasaka N Yamamoto K Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod Rheumatol 2009 19 1 12 19 18979150
   PubMed Web of Science ®Google Scholar
• Nishimoto N Hashimoto J Miyasaka N Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 2007 66 9 1162 1167 17485422
   PubMed Web of Science ®Google Scholar
• Kremer JM Blanco R Brzosko M Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year Arthritis Rheum 2011 63 3 609 621 21360490
   PubMed Web of Science ®Google Scholar
• Maini RN Taylor PC Szechinski J CHARISMA Study Group Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 2006 54 9 2817 2829 16947782
   PubMed Web of Science ®Google Scholar
• Smolen JS Beaulieu A Rubbert-Roth A OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 2008 371 9617 987 997 18358926
   PubMed Web of Science ®Google Scholar
• Genovese MC McKay JD Nasonov EL Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 2008 58 10 2968 2980 18821691
   PubMed Web of Science ®Google Scholar
• Yazici Y Curtis JR Ince A Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study) Clin Exp Rheumatol 2013 31 3 358 364 23305631
   PubMed Web of Science ®Google Scholar
• Emery P Keystone E Tony HP IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 2008 67 11 1516 1523 18625622
   PubMed Web of Science ®Google Scholar
• Dougados M Kissel K Sheeran T Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann Rheum Dis 2013 72 1 43 50 22562983
   PubMed Web of Science ®Google Scholar
• Weinblatt ME Kremer J Cush J Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study Arthritis Care Res (Hoboken) 2013 65 3 362 371 22972745
   PubMed Web of Science ®Google Scholar
• Jones G Sebba A Gu J Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 2010 69 1 88 96 19297346
   PubMed Web of Science ®Google Scholar
• Gabay C Emery P van Vollenhoven R ADACTA Study Investigators Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 2013 381 9877 1541 1550 23515142
   PubMed Web of Science ®Google Scholar
• Ogata A Tanimura K Sugimoto T A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI) Arthritis Care Res (Hoboken) Epub 8 27 2013
   Web of Science ®Google Scholar
• Burmester GR Rubbert-Roth A Cantagrel A A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) Ann Rheum Dis 2014 73 1 69 74 23904473
   PubMed Web of Science ®Google Scholar
• Singh JA Beg S Lopez-Olivo MA Tocilizumab for rheumatoid arthritis: a Cochrane systematic review J Rheumatol 2011 38 1 10 20 20952462
   PubMed Web of Science ®Google Scholar
• Levi M Grange S Frey N Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis J Clin Pharmacol 2013 53 2 151 159 23436260
   PubMed Web of Science ®Google Scholar
• Singh JA Wells GA Christensen R Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2011 2 CD008794 21328309
   PubMed Web of Science ®Google Scholar
• Lang VR Englbrecht M Rech J Risk of infections in rheumatoid arthritis patients treated with tocilizumab Rheumatology (Oxford) 2012 51 5 852 857 21865281
   PubMed Web of Science ®Google Scholar
• Schiff MH Kremer JM Jahreis A Vernon E Isaacs JD van Vollenhoven RF Integrated safety in tocilizumab clinical trials Arthritis Res Ther 2011 13 5 R141 21884601
   PubMed Web of Science ®Google Scholar
• Koike T Harigai M Inokuma S Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients Ann Rheum Dis 2011 70 12 2148 2151 21852254
   PubMed Web of Science ®Google Scholar
• Actemra® (tocilizumab) [package insert] South San Francisco Genentech, Inc. 2010
   Google Scholar
• Strang AC Bisoendial RJ Kootte RS Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis Atherosclerosis 2013 229 1 174 181 23746537
   PubMed Web of Science ®Google Scholar
• Genovese MC McKay JD Nasonov EL Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 2008 58 10 2968 2980 18821691
   PubMed Web of Science ®Google Scholar
• Smolen JS Schoels MM Nishimoto N Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions Ann Rheum Dis 2013 72 4 482 492 23172750
   PubMed Web of Science ®Google Scholar
• Dursunoğlu D Evrengül H Polat B Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation Rheumatol Int 2005 25 4 241 245 15290086
   PubMed Web of Science ®Google Scholar
• Kume K Amano K Yamada S Hatta K Ohta H Kuwaba N Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial J Rheumatol 2011 38 10 2169 2171 21807781
   PubMed Web of Science ®Google Scholar
• Schiff MH Kremer JM Jahreis A Vernon E Isaacs JD van Vollenhoven RF Integrated safety in tocilizumab clinical trials Arthritis Res Ther 2011 13 5 R141 21884601
   PubMed Web of Science ®Google Scholar
• Gout T Ostör AJ Nisar MK Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review Clin Rheumatol 2011 30 11 1471 1474 21833686
   PubMed Web of Science ®Google Scholar
• Genovese MC Rubbert-Roth A Smolen JS Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure J Rheumatol 2013 40 6 768 780 23457383
   PubMed Web of Science ®Google Scholar
• Bykerk VP Ostör AJ Alvaro-Gracia J Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice Ann Rheum Dis 2012 71 12 1950 1954 22615456
   PubMed Web of Science ®Google Scholar
• Bombardieri S Ruiz AA Fardellone P Research in Active Rheumatoid Arthritis (ReAct) Study Group Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Rheumatology (Oxford) 2007 46 7 1191 1199 17504821
   PubMed Web of Science ®Google Scholar
• Woodrick RS Ruderman EM Interleukin 6 inhibition – RA and beyond Bull NYU Hosp Jt Dis 2011 69 3 225 229 22035433
   PubMedGoogle Scholar
• Yokota S Imagawa T Mori M Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial Lancet 2008 371 9617 998 1006 18358927
   PubMed Web of Science ®Google Scholar
• Chen DY Lan JL Lin FJ Hsieh TY Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease J Rheumatol 2004 31 11 2189 2198 15517632
   PubMed Web of Science ®Google Scholar
• Puéchal X DeBandt M Berthelot JM Club Rhumatismes Et Inflammation Tocilizumab in refractory adult Still’s disease Arthritis Care Res (Hoboken) 2011 63 1 155 159 20740616
   PubMed Web of Science ®Google Scholar
• Nakahara H Mima T Yoshio-Hoshino N Matsushita M Hashimoto J Nishimoto N A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years Mod Rheumatol 2009 19 1 69 72 18762861
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M Deans RJ Wallace DJ Prehn J Ozeri-Chen T Klinenberg JR Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis J Immunol 1991 147 1 117 123 2051017
   PubMed Web of Science ®Google Scholar
• Illei GG Shirota Y Yarboro CH Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Arthritis Rheum 2010 62 2 542 552 20112381
   PubMed Web of Science ®Google Scholar
• Park MC Lee SW Park YB Lee SK Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis Rheumatology (Oxford) 2006 45 5 545 548 16352633
   PubMed Web of Science ®Google Scholar
• Tombetti E Franchini S Papa M Sabbadini MG Baldissera E Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center J Rheumatol 2013 40 12 2047 2051 24187104
   PubMed Web of Science ®Google Scholar
• Abisror N Mekinian A Lavigne C Vandenhende MA Soussan M Fain O Club Rhumatismes et Inflammation, and SNFMI Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review Autoimmun Rev 2013 12 12 1143 1149 23820042
   PubMed Web of Science ®Google Scholar
• Ishioka S Saito T Hiyama K Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 1996 13 2 139 145 8893383
   PubMed Web of Science ®Google Scholar
• Balamugesh T Behera D Bhatnagar A Majumdar S Inflammatory cytokine levels in induced sputum and bronchoalveolar lavage fluid in pulmonary sarcoidosis Indian J Chest Dis Allied Sci 2006 48 3 177 181 18610674
   PubMedGoogle Scholar
• Nutz A Pernet C Combe B Cohen JD Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol 2013 40 10 1773 1774 24085760
   PubMed Web of Science ®Google Scholar
• Larsson PT Hallerstam S Rosfors S Wallén NH Circulating markers of inflammation are related to carotid artery atherosclerosis Int Angiol 2005 24 1 43 51 15876998
   PubMed Web of Science ®Google Scholar
• Kume K Amano K Yamada S Hatta K Ohta H Kuwaba N Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial J Rheumatol 2011 38 10 2169 2171 21807781
   PubMed Web of Science ®Google Scholar
• Conway DS Buggins P Hughes E Lip GY Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation Am Heart J 2004 148 3 462 466 15389233
   PubMed Web of Science ®Google Scholar
• Ohtori S Miyagi M Eguchi Y Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica Eur Spine J 2012 21 10 2079 2084 22350007
   PubMed Web of Science ®Google Scholar
• Lin JT Wang JY Chen MK Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6 Exp Cell Res 2013 319 14 2216 2229 23751564
   PubMed Web of Science ®Google Scholar
• Okitsu K Kanda T Imazeki F Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer Genes Cancer 2010 1 8 859 867 21779469
   PubMedGoogle Scholar
• Ohishi W Cologne JB Fujiwara S Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study Int J Cancer 2014 134 1 154 163 23784949
   PubMed Web of Science ®Google Scholar
• Shinriki S Jono H Ota K Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma Clin Cancer Res 2009 15 17 5426 5434 19706815
   PubMed Web of Science ®Google Scholar
• Jordan SC Kahwaji J Toyoda M Vo A B-cell immunotherapeutics: emerging roles in solid organ transplantation Curr Opin Organ Transplant 2011 16 4 416 424 21666479
   PubMed Web of Science ®Google Scholar
• Cedars-Sinai Medical Center A safety study of tocilizumab to improve transplant rates in highly sensitized patients awaiting kidney transplantation Available from: http://clinicaltrials.gov/show/NCT01594424. NLM identifier: NCT01594424 Accessed November 1, 2013
   Google Scholar
• Weill Medical College of Cornell University Phase II study of tocilizumab for patients with glucocorticoid-refractory acute GVHD after allogeneic hematopoetic stem cell transplant (HSCT) Available from: http://clinicaltrials.gov/ct2/show/NCT01757197?term=NCT01757197&rank=1. NLM identifier: NCT01757197 Accessed November 1, 2013
   Google Scholar
• Sanofi To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) Available from http://clinicaltrials.gov/show/NCT01768572. NLM identifier: NCT01768572 Accessed November 1, 2013
   Google Scholar
• Janssen Research & Development A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND) Available from http://clinicaltrials.gov/ct2/show/NCT01606761?term=sirukumab&rank=2. NLM identifier: NCT01606761 Accessed November 1, 2013
   Google Scholar
• Sanofi Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01061736. NLM identifier: NCT01061736 Accessed November 1, 2013
   Google Scholar
• Hsu B Sheng S Smolen J Results from a 2-part, proof of concept, dose ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy Annals Rheumatic Diseases 2012 71 Suppl 3 188
   Web of Science ®Google Scholar